RAB23 and breast cancer: The survival analysis showed that BC patients expressing high levels of HS3ST3A1 and RAB23 had a poor prognosis (HS3ST3A1 p < 0.005, RAB23 p < 0.005, by log-rank test) (Figures 5B–E).